Literature DB >> 21471435

Alzheimer's disease: the challenge of the second century.

David M Holtzman1, John C Morris, Alison M Goate.   

Abstract

Alzheimer's disease (AD) was first described a little more than 100 years ago. It is the most common cause of dementia with an estimated prevalence of 30 million people worldwide, a number that is expected to quadruple in 40 years. There currently is no effective treatment that delays the onset or slows the progression of AD. However, major scientific advances in the areas of genetics, biochemistry, cell biology, and neuroscience over the past 25 years have changed the way we think about AD. This review discusses some of the challenges to translating these basic molecular and cellular discoveries into clinical therapies. Current information suggests that if the disease is detected before the onset of overt symptoms, it is possible that treatments based on knowledge of underlying pathogenesis can and will be effective.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21471435      PMCID: PMC3130546          DOI: 10.1126/scitranslmed.3002369

Source DB:  PubMed          Journal:  Sci Transl Med        ISSN: 1946-6234            Impact factor:   17.956


  213 in total

1.  Processing of the amyloid protein precursor to potentially amyloidogenic derivatives.

Authors:  T E Golde; S Estus; L H Younkin; D J Selkoe; S G Younkin
Journal:  Science       Date:  1992-02-07       Impact factor: 47.728

2.  Oligomeric amyloid beta associates with postsynaptic densities and correlates with excitatory synapse loss near senile plaques.

Authors:  Robert M Koffie; Melanie Meyer-Luehmann; Tadafumi Hashimoto; Kenneth W Adams; Matthew L Mielke; Monica Garcia-Alloza; Kristina D Micheva; Stephen J Smith; M Leo Kim; Virginia M Lee; Bradley T Hyman; Tara L Spires-Jones
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-19       Impact factor: 11.205

3.  Early-onset Alzheimer's disease caused by mutations at codon 717 of the beta-amyloid precursor protein gene.

Authors:  M C Chartier-Harlin; F Crawford; H Houlden; A Warren; D Hughes; L Fidani; A Goate; M Rossor; P Roques; J Hardy
Journal:  Nature       Date:  1991-10-31       Impact factor: 49.962

4.  Nicastrin modulates presenilin-mediated notch/glp-1 signal transduction and betaAPP processing.

Authors:  G Yu; M Nishimura; S Arawaka; D Levitan; L Zhang; A Tandon; Y Q Song; E Rogaeva; F Chen; T Kawarai; A Supala; L Levesque; H Yu; D S Yang; E Holmes; P Milman; Y Liang; D M Zhang; D H Xu; C Sato; E Rogaev; M Smith; C Janus; Y Zhang; R Aebersold; L S Farrer; S Sorbi; A Bruni; P Fraser; P St George-Hyslop
Journal:  Nature       Date:  2000-09-07       Impact factor: 49.962

5.  Mutations associated with a locus for familial Alzheimer's disease result in alternative processing of amyloid beta-protein precursor.

Authors:  C Haass; A Y Hung; D J Selkoe; D B Teplow
Journal:  J Biol Chem       Date:  1994-07-01       Impact factor: 5.157

Review 6.  Alzheimer's disease: a disorder of cortical cholinergic innervation.

Authors:  J T Coyle; D L Price; M R DeLong
Journal:  Science       Date:  1983-03-11       Impact factor: 47.728

7.  Validating predicted biological effects of Alzheimer's disease associated SNPs using CSF biomarker levels.

Authors:  John S K Kauwe; Carlos Cruchaga; Sarah Bertelsen; Kevin Mayo; Wayne Latu; Petra Nowotny; Anthony L Hinrichs; Anne M Fagan; David M Holtzman; Alison M Goate
Journal:  J Alzheimers Dis       Date:  2010       Impact factor: 4.472

8.  Fyn kinase modulates synaptotoxicity, but not aberrant sprouting, in human amyloid precursor protein transgenic mice.

Authors:  Jeannie Chin; Jorge J Palop; Gui-Qiu Yu; Nobuhiko Kojima; Eliezer Masliah; Lennart Mucke
Journal:  J Neurosci       Date:  2004-05-12       Impact factor: 6.167

9.  Amyloid deposition is associated with impaired default network function in older persons without dementia.

Authors:  Reisa A Sperling; Peter S Laviolette; Kelly O'Keefe; Jacqueline O'Brien; Dorene M Rentz; Maija Pihlajamaki; Gad Marshall; Bradley T Hyman; Dennis J Selkoe; Trey Hedden; Randy L Buckner; J Alex Becker; Keith A Johnson
Journal:  Neuron       Date:  2009-07-30       Impact factor: 17.173

10.  Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease.

Authors:  Adam C Naj; Gyungah Jun; Gary W Beecham; Li-San Wang; Badri Narayan Vardarajan; Jacqueline Buros; Paul J Gallins; Joseph D Buxbaum; Gail P Jarvik; Paul K Crane; Eric B Larson; Thomas D Bird; Bradley F Boeve; Neill R Graff-Radford; Philip L De Jager; Denis Evans; Julie A Schneider; Minerva M Carrasquillo; Nilufer Ertekin-Taner; Steven G Younkin; Carlos Cruchaga; John S K Kauwe; Petra Nowotny; Patricia Kramer; John Hardy; Matthew J Huentelman; Amanda J Myers; Michael M Barmada; F Yesim Demirci; Clinton T Baldwin; Robert C Green; Ekaterina Rogaeva; Peter St George-Hyslop; Steven E Arnold; Robert Barber; Thomas Beach; Eileen H Bigio; James D Bowen; Adam Boxer; James R Burke; Nigel J Cairns; Chris S Carlson; Regina M Carney; Steven L Carroll; Helena C Chui; David G Clark; Jason Corneveaux; Carl W Cotman; Jeffrey L Cummings; Charles DeCarli; Steven T DeKosky; Ramon Diaz-Arrastia; Malcolm Dick; Dennis W Dickson; William G Ellis; Kelley M Faber; Kenneth B Fallon; Martin R Farlow; Steven Ferris; Matthew P Frosch; Douglas R Galasko; Mary Ganguli; Marla Gearing; Daniel H Geschwind; Bernardino Ghetti; John R Gilbert; Sid Gilman; Bruno Giordani; Jonathan D Glass; John H Growdon; Ronald L Hamilton; Lindy E Harrell; Elizabeth Head; Lawrence S Honig; Christine M Hulette; Bradley T Hyman; Gregory A Jicha; Lee-Way Jin; Nancy Johnson; Jason Karlawish; Anna Karydas; Jeffrey A Kaye; Ronald Kim; Edward H Koo; Neil W Kowall; James J Lah; Allan I Levey; Andrew P Lieberman; Oscar L Lopez; Wendy J Mack; Daniel C Marson; Frank Martiniuk; Deborah C Mash; Eliezer Masliah; Wayne C McCormick; Susan M McCurry; Andrew N McDavid; Ann C McKee; Marsel Mesulam; Bruce L Miller; Carol A Miller; Joshua W Miller; Joseph E Parisi; Daniel P Perl; Elaine Peskind; Ronald C Petersen; Wayne W Poon; Joseph F Quinn; Ruchita A Rajbhandary; Murray Raskind; Barry Reisberg; John M Ringman; Erik D Roberson; Roger N Rosenberg; Mary Sano; Lon S Schneider; William Seeley; Michael L Shelanski; Michael A Slifer; Charles D Smith; Joshua A Sonnen; Salvatore Spina; Robert A Stern; Rudolph E Tanzi; John Q Trojanowski; Juan C Troncoso; Vivianna M Van Deerlin; Harry V Vinters; Jean Paul Vonsattel; Sandra Weintraub; Kathleen A Welsh-Bohmer; Jennifer Williamson; Randall L Woltjer; Laura B Cantwell; Beth A Dombroski; Duane Beekly; Kathryn L Lunetta; Eden R Martin; M Ilyas Kamboh; Andrew J Saykin; Eric M Reiman; David A Bennett; John C Morris; Thomas J Montine; Alison M Goate; Deborah Blacker; Debby W Tsuang; Hakon Hakonarson; Walter A Kukull; Tatiana M Foroud; Jonathan L Haines; Richard Mayeux; Margaret A Pericak-Vance; Lindsay A Farrer; Gerard D Schellenberg
Journal:  Nat Genet       Date:  2011-04-03       Impact factor: 38.330

View more
  551 in total

1.  Alzheimer's Disease Risk Factor Pyk2 Mediates Amyloid-β-Induced Synaptic Dysfunction and Loss.

Authors:  Santiago V Salazar; Timothy O Cox; Suho Lee; A Harrison Brody; Annabel S Chyung; Laura T Haas; Stephen M Strittmatter
Journal:  J Neurosci       Date:  2018-12-05       Impact factor: 6.167

Review 2.  Gains or losses: molecular mechanisms of TDP43-mediated neurodegeneration.

Authors:  Edward B Lee; Virginia M-Y Lee; John Q Trojanowski
Journal:  Nat Rev Neurosci       Date:  2011-11-30       Impact factor: 34.870

3.  Toward a multifactorial model of Alzheimer disease.

Authors:  Martha Storandt; Denise Head; Anne M Fagan; David M Holtzman; John C Morris
Journal:  Neurobiol Aging       Date:  2012-01-20       Impact factor: 4.673

4.  Contribution of the γ-secretase subunits to the formation of catalytic pore of presenilin 1 protein.

Authors:  Koji Takeo; Naoto Watanabe; Taisuke Tomita; Takeshi Iwatsubo
Journal:  J Biol Chem       Date:  2012-06-11       Impact factor: 5.157

5.  Cerebral amyloid angiopathy in an aged sooty mangabey (Cercocebus atys).

Authors:  Olivia M D'Angelo; Jeromy Dooyema; Cynthia Courtney; Lary C Walker; Eric Heuer
Journal:  Comp Med       Date:  2013       Impact factor: 0.982

Review 6.  Flavonoids as therapeutic compounds targeting key proteins involved in Alzheimer's disease.

Authors:  Filipa I Baptista; Ana G Henriques; Artur M S Silva; Jens Wiltfang; Odete A B da Cruz e Silva
Journal:  ACS Chem Neurosci       Date:  2014-01-03       Impact factor: 4.418

7.  Generation of Clickable Pittsburgh Compound B for the Detection and Capture of β-Amyloid in Alzheimer's Disease Brain.

Authors:  Ian Diner; Jeromy Dooyema; Marla Gearing; Lary C Walker; Nicholas T Seyfried
Journal:  Bioconjug Chem       Date:  2017-09-22       Impact factor: 4.774

8.  Innate immunity receptor CD36 promotes cerebral amyloid angiopathy.

Authors:  Laibaik Park; Joan Zhou; Ping Zhou; Rose Pistick; Sleiman El Jamal; Linda Younkin; Joseph Pierce; Andrea Arreguin; Josef Anrather; Steven G Younkin; George A Carlson; Bruce S McEwen; Costantino Iadecola
Journal:  Proc Natl Acad Sci U S A       Date:  2013-02-04       Impact factor: 11.205

Review 9.  Shared cognitive and behavioral impairments in epilepsy and Alzheimer's disease and potential underlying mechanisms.

Authors:  Jeannie Chin; Helen E Scharfman
Journal:  Epilepsy Behav       Date:  2013-01-13       Impact factor: 2.937

10.  Functional connectivity and graph theory in preclinical Alzheimer's disease.

Authors:  Matthew R Brier; Jewell B Thomas; Anne M Fagan; Jason Hassenstab; David M Holtzman; Tammie L Benzinger; John C Morris; Beau M Ances
Journal:  Neurobiol Aging       Date:  2013-10-18       Impact factor: 4.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.